Business Wire

NY-PRODAPT

Share
Prodapt Wins the Prestigious Salesforce Partner Innovation Award 2022

Prodapt, a leading global consulting, technology & managed services provider with a singular focus on the Connectedness industry, has been named a recipient of the Salesforce Partner Innovation Award in the "Communications" category. The prestigious award recognizes Prodapt’s contributions to Salesforce-driven digital transformation programs and the development of specific solution accelerators for the communications industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005351/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prodapt is the winner of the Salesforce Partner Innovation Award 2022 in the Communications category (Graphic: Business Wire)

Each year, the Salesforce Partner Innovation Awards recognize the significant contributions Salesforce partners have made across clouds, industries, and the broader partner program – including consulting firms, digital agencies, resellers, and ISV partners. IDC, a global provider of market intelligence and advisory services for the IT, telecommunications, and consumer technology markets, facilitated and judged the nominations.

Prodapt tendered its nomination for the CRM transformation of Fiber Network Delivery to support multiple new operating models. The award affirms Prodapt’s continuous efforts in delivering value to its global clients by accelerating its transformation initiatives.

“In today’s world of fierce competition, customer volatility, and economic uncertainty, excellence in innovation has become a critical differentiator. The Partner Innovation Award in the Communications space signifies our track record in facilitating end-to-end CRM transformations that deliver business outcomes, leveraging our deep industry expertise.” – Smita Katariya | Vice President, Prodapt.

“Salesforce Partner Innovation Award winners, such as Prodapt, help customers grow faster and reach further in this new digital economy,” said Tyler Prince, Executive Vice President, Alliances & Channels at Salesforce. “Salesforce partners are integral to enabling digital transformation and driving customer success.”

For further details on Salesforce Partner Innovation Awards, visit: https://www.salesforce.com/news/stories/salesforce-2022-partner-innovation-award-winners/

Salesforce and others are among the trademarks of Salesforce.com, Inc.

About Prodapt

Prodapt is the largest and fastest-growing EXCLUSIVE player in the Connectedness space, serving global firms that ultimately seek to connect people.

Prodapt prides itself on long-tenured client relationships and has always been considered a valuable partner by clients. Prodapt serves global leaders across telecom, internet, media, and entertainment, such as Google, Facebook, Amazon, Microsoft, AT&T, Verizon, Liberty Latin America, Lumen, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, KPN, BT, and Deutsche Telekom, among many others.

Prodapt is A Great Place to Work certified company with a workforce of over 5000 spread across 32 countries spanning the Americas, Europe, Africa, and Asia. Prodapt is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005351/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye